Blue Trust Inc. Invests $468,000 in Cellebrite DI Ltd. (NASDAQ:CLBT)

Blue Trust Inc. purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 21,226 shares of the company's stock, valued at approximately $468,000.

A number of other institutional investors have also recently added to or reduced their stakes in CLBT. Quarry LP acquired a new stake in Cellebrite DI during the 3rd quarter worth $27,000. Advisors Asset Management Inc. raised its holdings in shares of Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock worth $52,000 after acquiring an additional 1,742 shares during the period. Pathway Financial Advisers LLC raised its holdings in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock worth $74,000 after acquiring an additional 4,118 shares during the period. R Squared Ltd purchased a new position in shares of Cellebrite DI during the 4th quarter worth $100,000. Finally, Venturi Wealth Management LLC raised its holdings in shares of Cellebrite DI by 28.6% during the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock worth $152,000 after acquiring an additional 2,000 shares during the period. Institutional investors and hedge funds own 45.88% of the company's stock.

Analyst Upgrades and Downgrades

CLBT has been the topic of several analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price target on shares of Cellebrite DI in a report on Friday, February 14th. Lake Street Capital lifted their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Craig Hallum lifted their price target on Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $23.43.

Cellebrite DI Trading Up 0.3 %

CLBT traded up $0.05 on Friday, hitting $19.12. The company had a trading volume of 3,548,554 shares, compared to its average volume of 2,077,086. The firm has a market cap of $3.94 billion, a P/E ratio of -13.76, a PEG ratio of 4.40 and a beta of 1.47. Cellebrite DI Ltd. has a 1 year low of $10.24 and a 1 year high of $26.30. The company's fifty day moving average price is $22.55 and its 200 day moving average price is $19.33.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.